SPC25: A Potential Drug Target for Neurological Disorders (G57405)

Target Name: SPC25

NCBI ID: G57405

SPC25

SPC25: A Potential Drug Target for Neurological Disorders

SPC25 (2600017H08Rik), also known as ALZ1218, is a protein that is expressed in the brain and has been shown to play a role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is currently being investigated as a potential drug target (or biomarker) for the treatment of these disorders.

SPC25 is a transmembrane protein that is expressed in the brain and has been shown to be involved in the formation of neurotransmitter receptors. These receptors are responsible for transmitting signals from the brain to the rest of the body and are crucial for the proper functioning of the nervous system. SPC25 has been shown to play a role in the regulation of neurotransmitter receptors, which may be important for the treatment of neurological disorders.

One of the most promising aspects of SPC25 is its potential as a drug target. The protein is thought to be involved in the development and progression of Alzheimer's disease, a condition that is characterized by the progressive loss of brain cells and the formation of aggregates of the protein beta-amyloid. By targeting SPC25, researchers may be able to reduce the formation of beta-amyloid and slow the progression of Alzheimer's disease.

SPC25 has also been shown to be involved in the regulation of other neurological disorders, including Parkinson's disease and multiple sclerosis. In these conditions, the protein is thought to be involved in the formation of neurotransmitter receptors and the regulation of the immune response.

In addition to its potential as a drug target, SPC25 also has potential as a biomarker. The protein is thought to be expressed in the brain and may be a useful marker for the early detection of neurological disorders. This could be important for the development of new treatments for these disorders, as earlier intervention is often more effective.

Overall, SPC25 is a protein that is being investigated as a potential drug target (or biomarker) for the treatment of neurological disorders. Its role in the regulation of neurotransmitter receptors and its potential as a marker for the early detection of disorders makes it an attractive target for research in this field. Further studies are needed to fully understand the role of SPC25 in these conditions and to determine its potential as a drug.

Protein Name: SPC25 Component Of NDC80 Kinetochore Complex

Functions: Acts as a component of the essential kinetochore-associated NDC80 complex, which is required for chromosome segregation and spindle checkpoint activity (PubMed:14699129, PubMed:14738735). Required for kinetochore integrity and the organization of stable microtubule binding sites in the outer plate of the kinetochore (PubMed:14738735, PubMed:14699129). The NDC80 complex synergistically enhances the affinity of the SKA1 complex for microtubules and may allow the NDC80 complex to track depolymerizing microtubules (PubMed:23085020)

The "SPC25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPC25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets